
Pembrolizumab KEYNOTE-017





FINAL SCORE				
CURATIVE				
Overall Survival / Dise	ase-Free Survival /	Pathological Comp	lete Response	
NON-CURATIVE				
Overall Survival				
Progression-Free Sur	vival			
Non-inferiority (Improv	ed Quality of Life or	Reduced Adverse	Events) / Response Rate	
	•	3		
Overall Response Rat	e / Duration of Resp	oonse		
Overall Survival / Dise	ase-Free Survival /	Pathological Comp	lete Response	
INFORMATION				
Tumour type: Skin C Therapeutic Indicati or metastatic Merke Experimental Arm: F	on: Adult and ped I cell carcinoma	iatric patients with	n recurrent, locally advanc	ced

